生命科学资讯

Stryker promotes new president, COO to help lead its M&A strategy

Mirum beckons Bluejay and its phase 3-stage hepatitis drug for $620M

Wave, Structure stocks double on obesity data readouts

Dyne readies FDA push after DMD exon 51 med excels in trial

Dr. Reddy's pens $370M pact for rights to Immutep's phase 3-stage immunotherapy in certain markets

AbbVie hands back phase 1 duties for chronic inflammation drug to partner OSE

ASH: Anito-cel strengthens best-in-class potential as Gilead's Kite preps for launch

ASH: Star antibody sparkles in preview of potential phase 3 bleeding disease success

‘Market’s thinking is backwards’: FDA’s 1-trial approval plan would boost R&D spend, Jefferies says

FDA panel votes against J&J's novel shunt implant for heart failure

Natera buys Foresight Diagnostics in cancer testing deal worth up to $450M

Encoded deciphers path to pivotal trial with phase 1/2 Dravet gene therapy data

'Unprecedented turmoil' engulfing FDA threatens public health: mRNA coalition speaks out

How AI and real-world evidence are powering smarter decisions across the drug and device development lifecycle

A New Era in Parkinson’s: Solengepras Leads the Shift Beyond Dopamine

Chutes & Ladders—Yet another CDER leadership shake-up

Praxis claims efficacy success in phase 2 seizure trial, setting up approval talks with FDA

Cancer blood test developer Freenome to go public in $330M SPAC deal

Pfizer Ventures gets behind Chinese biotech's $100M series A to boost R&D hub's capability

FDA slaps hold on Denali's plans for phase 1 rare disease trial